GO:0031399 regulation of protein modification process: Signaling Hub, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031399 regulation of protein modification process describes any process that modulates the frequency, rate or extent of the covalent alteration of amino acid residues within a protein.
• This regulatory term encompasses phosphorylation, ubiquitination, SUMOylation, acetylation, glycosylation, and other post-translational modifications (PTMs) that control protein function, stability, and interactions [1, 3, 4].
• Key effector families include E3 ubiquitin ligases, deubiquitinating enzymes (DUBs), SUMO-conjugating enzymes, histone acetyltransferases (HATs), and kinases [4, 6, 7].
• Dysregulation of protein modification processes is implicated in cancer, cardiovascular disease, neurodegeneration, and ferroptosis [2, 5, 8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of regulatory nodes within this process [4, 7].
• Integrative methods such as proteomics, ubiquitinome profiling, and CRISPR library screening are essential for mapping regulatory networks under GO:0031399 [3, 6].
Description
The Gene Ontology (GO) term GO:0031399, regulation of protein modification process, defines any process that modulates the frequency, rate or extent of the covalent alteration of one or more amino acid residues within a protein. This term sits at the heart of cellular signaling because post-translational modifications (PTMs) such as phosphorylation, ubiquitination, SUMOylation, acetylation, and glycosylation dynamically alter protein activity, localization, stability, and interaction networks [1, 3, 4]. Researchers studying signal transduction, proteostasis, and disease mechanisms require a precise understanding of how these modifications are regulated. The regulatory layer includes enzymes that add or remove modifications (writers and erasers), substrate recognition factors, and scaffolding proteins that spatially and temporally organize modification events [4, 6, 7]. Because PTM dysregulation underlies numerous pathologies, from cancer to cardiovascular disease and ferroptosis, GO:0031399 provides a conceptual framework for investigating both basic biology and therapeutic targets [2, 5, 8].
regulation of protein modification process At A Glance
| GO ID | GO:0031399 |
|---|---|
| GO term | regulation of protein modification process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of covalent alteration of amino acid residues within a protein |
| Examples of modifications | Phosphorylation, ubiquitination, SUMOylation, acetylation, glycosylation, crotonylation |
| Key enzyme families | E3 ligases, DUBs, SUMO conjugating enzymes, HATs, kinases |
| Disease relevance | Cancer, cardiovascular disease, neurodegeneration, ferroptosis |
What Is GO:0031399?
In our own words, GO:0031399 encompasses any biological process that controls the addition, removal, or alteration of covalent chemical groups on amino acid residues within a protein. This includes the regulation of enzymatic activities (e.g., kinases, ubiquitin ligases, deubiquitinases, SUMO proteases), the availability of substrates and cofactors, and the spatial-temporal coordination of modification reactions. The term is not restricted to a single type of modification; rather, it integrates regulatory inputs that determine when, where, and how a protein is covalently modified [1, 3, 4].
Why Is regulation of protein modification process Important in Cell Biology?
Regulation of protein modification processes is fundamental to virtually all cellular signaling pathways, as it determines the fate and function of proteins in response to internal and external cues [1, 3, 4]. Disruption of these regulatory mechanisms leads to aberrant protein activity or stability, which is a common driver of human disease, including cancer, cardiovascular disorders, and ferroptosis [2, 5, 8]. Understanding GO:0031399 therefore provides mechanistic insights into disease pathogenesis and identifies potential targets for therapeutic intervention.
• Controls protein stability and degradation via ubiquitin-proteasome system and autophagy [2, 7].
• Regulates gene expression through histone modifications and chromatin remodeling [1, 8].
• Modulates signal transduction cascades by reversible phosphorylation and SUMOylation [3, 6].
• Impacts cardiovascular health through protein glycosylation changes.
• Plays a central role in ferroptosis by regulating iron metabolism and lipid peroxidation proteins.
• Dysregulation is linked to cancer, neurodegeneration, and metabolic disorders [4, 6, 7].
• Provides targets for drug discovery, e.g., E3 ligase inhibitors and DUB inhibitors [4, 7].
• Essential for understanding cellular responses to stress and oxidative damage.
What Happens During regulation of protein modification process?
Substrate recognition and recruitment
In simple terms: First, the right protein must be chosen for modification.
Regulation begins with the specific recognition of substrate proteins by modification enzymes. For ubiquitination, E3 ligases bind target proteins through degrons or adaptor proteins, ensuring selectivity. SUMOylation relies on SUMO E3 ligases that recognize consensus motifs or interact with substrate-binding partners. This step is tightly controlled to prevent unwanted modifications.
Catalytic modification and cofactor availability
In simple terms: Then, the chemical tag is attached using energy and helper molecules.
The actual covalent addition of modifiers (e.g., ubiquitin, SUMO, acetyl, phosphate) requires specific enzymes and cofactors. Ubiquitination uses E1, E2, and E3 enzymes in a cascade, consuming ATP. SUMOylation similarly requires E1 (SAE1/SAE2) and E2 (UBC9) enzymes. Acetylation by HATs uses acetyl-CoA as a donor. Regulation of cofactor levels and enzyme activity directly impacts modification rates.
Reversal and editing by eraser enzymes
In simple terms: Tags can be removed or changed by other enzymes.
Deubiquitinating enzymes (DUBs) remove ubiquitin from substrates, counteracting E3 ligase activity and recycling ubiquitin. SUMO proteases (SENPs) deconjugate SUMO. Histone deacetylases (HDACs) remove acetyl groups. This reversible nature allows dynamic regulation of protein function.
Spatiotemporal coordination and scaffolding
In simple terms: The modification happens at the right place and time thanks to organizing proteins.
Scaffold proteins and localization signals ensure that modification enzymes meet their substrates at the correct subcellular location and time. For example, SUMOylation often occurs in nuclear bodies or at DNA damage sites, guided by interaction partners. Ubiquitin ligases are recruited to specific compartments via adaptors. This spatial control is a key aspect of regulation.
Integration with cellular signaling and feedback
In simple terms: The process is tuned by signals from inside and outside the cell.
Modification processes are regulated by upstream signaling pathways, such as kinase cascades that phosphorylate E3 ligases or DUBs to alter their activity [4, 7]. Feedback loops exist: for instance, ubiquitination can trigger degradation of the modifying enzyme itself. SUMOylation is enhanced under stress conditions and regulates many transcription factors [3, 6]. This integration ensures cellular homeostasis.
Key Genes Involved in GO:0031399 regulation of protein modification process
The following genes encode key enzymes and regulatory components that directly participate in or regulate protein modification processes under GO:0031399.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UBE3A | E3 ubiquitin ligase | Angelman syndrome; ubiquitination regulation |
| MDM2 | E3 ubiquitin ligase for p53 | Cancer; ubiquitination and degradation |
| TRIM28 | E3 ligase; SUMOylation cofactor | Transcription regulation; chromatin modification |
| SUMO1 | SUMO modifier | SUMOylation; stress response |
| UBC9 (UBE2I) | SUMO E2 conjugating enzyme | Essential for SUMOylation |
| SENP1 | SUMO protease | De-SUMOylation; cancer |
| HDAC1 | Histone deacetylase | Chromatin remodeling; cancer |
| EP300 | Histone acetyltransferase | Acetylation; embryo development |
| CREBBP | Histone acetyltransferase | Transcription regulation; cancer |
| USP7 | Deubiquitinating enzyme | p53 stability; cancer |
| USP14 | Deubiquitinating enzyme | Proteasome regulation; neurodegeneration |
| OTUB1 | Deubiquitinating enzyme | DNA damage response; cancer |
| RNF168 | E3 ubiquitin ligase | DNA damage response; ubiquitination |
| PIAS1 | SUMO E3 ligase | Transcription regulation; SUMOylation |
| OGT | O-GlcNAc transferase | Glycosylation; cardiovascular disease |
| OGA | O-GlcNAcase | Glycosylation; neurodegeneration |
| GPX4 | Glutathione peroxidase; regulated by ubiquitination | Ferroptosis; protein modification |
How Is regulation of protein modification process Regulated?
The regulation of protein modification processes is itself controlled at multiple levels. Upstream signaling kinases can phosphorylate E3 ligases, DUBs, or SUMO enzymes to modulate their activity [4, 7]. For example, DNA damage activates ATM/ATR kinases, which phosphorylate downstream effectors to trigger ubiquitination and SUMOylation cascades. Oxidative stress regulates DUB activity through reversible oxidation of catalytic cysteines. Additionally, the availability of cofactors such as acetyl-CoA, ATP, and SUMO peptides influences modification rates [1, 3]. Feedback mechanisms include auto-ubiquitination of E3 ligases and de-SUMOylation by SENPs, ensuring homeostasis [4, 6].
regulation of protein modification process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MDM2 | Cancer (p53 degradation) | Knockout in cancer cell lines; point mutation of ubiquitin ligase domain |
| USP7 | Cancer (oncoprotein stabilization) | Knockout; overexpression; DUB inhibitor studies |
| OGT | Cardiovascular disease (glycosylation) | Knockout in cardiomyocytes; knock-in of O-GlcNAc sites |
| GPX4 | Ferroptosis | Knockout; point mutation of ubiquitination sites; overexpression |
| SENP1 | Cancer (SUMOylation imbalance) | Knockout; knock-in of catalytic mutant |
Cancer
Dysregulation of protein modification processes is a hallmark of cancer. Overexpression of E3 ligases such as MDM2 leads to p53 degradation, promoting tumorigenesis. DUBs like USP7 stabilize oncoproteins, and their inhibition is a therapeutic strategy. Altered histone acetylation and methylation patterns drive aberrant gene expression in cancer. SUMOylation regulates many oncogenic transcription factors and is often upregulated in tumors.
Cardiovascular disease
Protein glycosylation, particularly O-GlcNAcylation, plays a critical role in cardiovascular health and disease. Changes in OGT and OGA expression are associated with heart failure and diabetic cardiomyopathy. SUMOylation also protects against cardiac ischemia-reperfusion injury by modifying key signaling proteins.
Neurodegeneration
Impaired ubiquitin-proteasome system and DUB dysfunction contribute to neurodegenerative diseases such as Alzheimer's and Parkinson's. USP14 and OTUB1 are implicated in neuronal survival and protein aggregation. SUMOylation of proteins like alpha-synuclein may influence aggregation.
Ferroptosis
Ferroptosis is a form of regulated cell death driven by iron-dependent lipid peroxidation. Protein modifications, including ubiquitination and phosphorylation, regulate key ferroptosis regulators such as GPX4 and SLC7A11. Targeting these modification pathways is a potential therapeutic approach.
From regulation of protein modification process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of E3 ligase X affect substrate ubiquitination? | CRISPR knockout cell line |
| Does phosphorylation of DUB Y regulate its activity? | Point mutation (phospho-dead/phospho-mimetic) knock-in |
| Does SUMOylation of protein Z control its localization? | Knock-in of SUMO acceptor mutant |
| Can overexpression of OGT rescue glycosylation defects? | Overexpression cell model |
| Which genes regulate ferroptosis via ubiquitination? | CRISPR library screening |
| How does a disease-associated mutation alter modification? | Knock-in of patient mutation |
How to Study the regulation of protein modification process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ubiquitin remnant profiling | Ubiquitination sites on proteins | Global changes in ubiquitination after drug treatment |
| SUMO remnant profiling | SUMOylation sites | Identification of SUMO substrates under stress |
| CRISPR knockout screen | Gene essentiality or modifier of phenotype | Discovery of regulators of ferroptosis |
| BioID/APEX | Proximity interactome of enzyme | Mapping E3 ligase substrates |
| In vitro ubiquitination assay | Enzyme kinetics and substrate specificity | Testing mutant E3 ligases |
| Phospho-proteomics | Phosphorylation sites and dynamics | Signaling pathway analysis |
| Glycoproteomics | Glycosylation sites and occupancy | Cardiovascular disease biomarker discovery |
Proteomics and PTM-specific enrichment
Mass spectrometry-based proteomics coupled with enrichment of modified peptides (e.g., ubiquitin remnant profiling, SUMO remnant profiling) allows global mapping of modification sites and quantification of changes upon regulatory perturbations [3, 6]. This is essential for understanding the scope of GO:0031399.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate specific protein modification events, such as ferroptosis sensitivity or drug response. Libraries targeting E3 ligases, DUBs, and SUMO enzymes are particularly useful.
Imaging and proximity labeling
Fluorescence microscopy and proximity-dependent biotinylation (BioID, APEX) can visualize where and when modifications occur, and identify interacting partners of modification enzymes [4, 6]. These methods provide spatial context.
Biochemical assays and in vitro reconstitution
In vitro ubiquitination or SUMOylation assays using recombinant E1, E2, E3, and substrate proteins allow mechanistic dissection of regulatory steps [4, 6]. Kinetic analyses reveal how mutations or inhibitors affect enzyme activity.
How CRISPR Can Be Used to Study GO:0031399 regulation of protein modification process
Knockout
CRISPR knockout of genes encoding modification enzymes (e.g., E3 ligases, DUBs, SUMO proteases) creates loss-of-function models to study their role in protein modification processes. For example, knocking out MDM2 stabilizes p53 and affects cell cycle. Knockout of SENP1 alters SUMOylation homeostasis.
Point Mutation
Point mutations can be introduced to ablate catalytic activity or specific regulatory sites. For instance, a catalytic cysteine-to-alanine mutation in a DUB inactivates its deubiquitinating activity. Phospho-dead or phospho-mimetic mutations in E3 ligases reveal phosphorylation-dependent regulation.
Knock-in
Knock-in of tagged versions (e.g., HA, FLAG, GFP) of modification enzymes allows endogenous expression and interaction studies. Knock-in of substrate proteins with mutated modification sites (e.g., lysine-to-arginine for ubiquitination) prevents specific modifications [3, 6].
Overexpression
Overexpression of wild-type or mutant modification enzymes can amplify or disrupt modification pathways. For example, overexpressing OGT increases O-GlcNAcylation and protects against cardiovascular stress. Overexpression of SUMO1 enhances global SUMOylation.
How EDITGENE Supports regulation of protein modification process Research
Researchers studying regulation of protein modification process-related genes often need to determine whether a candidate gene is causally involved in a specific modification event or disease phenotype. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of regulatory components within GO:0031399.
Contact EDITGENE today to design your custom CRISPR model for regulation of protein modification process research.
Frequently Asked Questions About regulation of protein modification process
What is GO:0031399 regulation of protein modification process?
GO:0031399 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of the covalent alteration of one or more amino acid residues within a protein.
What genes are involved in regulation of protein modification process?
Key genes include E3 ubiquitin ligases (e.g., MDM2, UBE3A), deubiquitinating enzymes (e.g., USP7, USP14), SUMO enzymes (e.g., UBC9, SENP1), histone acetyltransferases (e.g., EP300, CREBBP), and glycosylation enzymes (e.g., OGT, OGA) [1, 3, 4, 5, 6, 7, 8].
How is protein modification regulated?
Protein modification is regulated by the activity, localization, and substrate recognition of writer and eraser enzymes, as well as cofactor availability and upstream signaling [1, 3, 4, 6, 7].
What diseases are associated with dysregulated protein modification?
Dysregulation is linked to cancer, cardiovascular disease, neurodegeneration, and ferroptosis [2, 4, 5, 6, 7].
What are examples of protein modifications?
Examples include ubiquitination, SUMOylation, phosphorylation, acetylation, glycosylation, and crotonylation [1, 2, 3, 4, 5, 8].
How can CRISPR be used to study regulation of protein modification?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of modification enzymes and substrate sites [4, 6, 7].
What methods are used to study protein modification processes?
Common methods include proteomics, PTM-specific enrichment, CRISPR screens, imaging, and biochemical assays [3, 4, 6].
What is the role of ubiquitination in ferroptosis?
Ubiquitination regulates the stability of key ferroptosis proteins such as GPX4, influencing lipid peroxidation and cell death.
How does SUMOylation regulate protein function?
SUMOylation alters protein interactions, localization, and activity, often in response to stress, and is reversed by SENP proteases [3, 6].
Why is regulation of protein modification important for drug discovery?
Many enzymes in this process are druggable targets; inhibitors of E3 ligases, DUBs, and kinases are under development for cancer and other diseases [4, 7].
Conclusion
GO:0031399 regulation of protein modification process is a central node in cellular signaling, integrating diverse post-translational modifications that control protein fate and function. Its dysregulation contributes to major human diseases, making it a rich area for both basic and translational research. CRISPR-based models and advanced proteomic methods are indispensable for dissecting the regulatory mechanisms and identifying therapeutic targets within this process.
References
- 1. Bannister AJ et al.. 2011. Regulation of chromatin by histone modifications.. Cell Res 21(3):381-95 PMID: 21321607
- 2. Wang Y et al.. 2024. Protein modification and degradation in ferroptosis.. Redox Biol 75:103259 PMID: 38955112
- 3. Chang HM et al.. 2020. SUMO: From Bench to Bedside.. Physiol Rev 100(4):1599-1619 PMID: 32666886
- 4. Toma-Fukai S et al.. 2021. Structural Diversity of Ubiquitin E3 Ligase.. Molecules 26(21) PMID: 34771091
- 5. Chatham JC et al.. 2024. Protein glycosylation in cardiovascular health and disease.. Nat Rev Cardiol 21(8):525-544 PMID: 38499867
- 6. Vertegaal ACO. 2022. Signalling mechanisms and cellular functions of SUMO.. Nat Rev Mol Cell Biol 23(11):715-731 PMID: 35750927
- 7. Snyder NA et al.. 2021. Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response.. J Biol Chem 297(3):101077 PMID: 34391779
- 8. Gao D et al.. 2024. P300 regulates histone crotonylation and preimplantation embryo development.. Nat Commun 15(1):6418 PMID: 39080296
